Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 2
1973 11
1974 11
1975 31
1976 33
1977 31
1978 24
1979 18
1980 18
1981 57
1982 34
1983 51
1984 48
1985 59
1986 84
1987 72
1988 96
1989 106
1990 115
1991 118
1992 125
1993 116
1994 129
1995 108
1996 120
1997 110
1998 117
1999 87
2000 88
2001 97
2002 85
2003 93
2004 90
2005 73
2006 87
2007 78
2008 93
2009 80
2010 82
2011 82
2012 70
2013 57
2014 73
2015 85
2016 70
2017 76
2018 44
2019 68
2020 66
2021 76
2022 59
2023 58
2024 71
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,625 results

Results by year

Filters applied: . Clear all
Page 1
Bumetanide, a Diuretic That Can Help Children with Autism Spectrum Disorder.
Shaker E, El Agami O, Salamah A. Shaker E, et al. CNS Neurol Disord Drug Targets. 2024;23(4):536-542. doi: 10.2174/1871527322666230404114911. CNS Neurol Disord Drug Targets. 2024. PMID: 37021422 Clinical Trial.
Group 1 received Bumetanide, Group 2 received a placebo for 6 months. Follow-up by CARS rating scale was performed before and after 1, 3, and 6 months of treatment. RESULTS: The use of bumetanide in group 1 improved the core symptoms of ASD in a shorter time with mi …
Group 1 received Bumetanide, Group 2 received a placebo for 6 months. Follow-up by CARS rating scale was performed before and after 1 …
Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance.
Verbrugge FH, Martens P, Ameloot K, Haemels V, Penders J, Dupont M, Tang WHW, Droogné W, Mullens W. Verbrugge FH, et al. Eur J Heart Fail. 2019 Nov;21(11):1415-1422. doi: 10.1002/ejhf.1478. Epub 2019 May 9. Eur J Heart Fail. 2019. PMID: 31074184 Free article. Clinical Trial.
Patients were randomised towards acetazolamide 250-500 mg daily plus bumetanide 1-2 mg bid vs. high-dose loop diuretics (bumetanide bid with daily dose twice the oral maintenance dose). ...Loop diuretic efficiency, defined as natriuresis corrected for loop diuretic …
Patients were randomised towards acetazolamide 250-500 mg daily plus bumetanide 1-2 mg bid vs. high-dose loop diuretics (bumetanid
Bumetanide induces post-traumatic microglia-interneuron contact to promote neurogenesis and recovery.
Tessier M, Garcia MS, Goubert E, Blasco E, Consumi A, Dehapiot B, Tian L, Molinari F, Laurin J, Guillemot F, Hübner CA, Pellegrino C, Rivera C. Tessier M, et al. Brain. 2023 Oct 3;146(10):4247-4261. doi: 10.1093/brain/awad132. Brain. 2023. PMID: 37082944 Free PMC article.
Although the Na-K-Cl cotransporter (NKCC1) inhibitor bumetanide has prominent positive effects on the pathophysiology of many neurological disorders, the mechanism of action is obscure. ...We used a combination of conditional transgenic animals, in vivo electrophysiology, …
Although the Na-K-Cl cotransporter (NKCC1) inhibitor bumetanide has prominent positive effects on the pathophysiology of many neurolo …
CNS pharmacology of NKCC1 inhibitors.
Löscher W, Kaila K. Löscher W, et al. Neuropharmacology. 2022 Mar 1;205:108910. doi: 10.1016/j.neuropharm.2021.108910. Epub 2021 Dec 6. Neuropharmacology. 2022. PMID: 34883135 Free article. Review.
Bumetanide is known to have anticonvulsant and neuroprotective effects under some pathophysiological conditions. ...The main outcomes are that (1), non-acidic loop diuretics such as azosemide and torasemide may have advantages as NKCC1 inhibitors vs. bumetanide; (2)
Bumetanide is known to have anticonvulsant and neuroprotective effects under some pathophysiological conditions. ...The main outcomes
A Double-Blind, Randomized, Placebo-Controlled Trial of Bumetanide in Parkinson's Disease.
Damier P, Degos B, Castelonovo G, Anheim M, Benatru I, Carrière N, Colin O, Defebvre L, Deverdal M, Eusebio A, Ferrier V, Giordana C, Houeto JL, Le Dily S, Mongin M, Thiriez C, Tranchant C, Ravel D, Corvol JC, Rascol O, Ben Ari Y. Damier P, et al. Mov Disord. 2024 Mar;39(3):618-622. doi: 10.1002/mds.29726. Epub 2024 Jan 30. Mov Disord. 2024. PMID: 38291616 Clinical Trial.
No changes between participants treated with bumetanide and those treated with placebo were observed for most other outcome measures. Despite no relevant safety signals, bumetanide was poorly tolerated. CONCLUSIONS: There was no evidence in this study that bumeta
No changes between participants treated with bumetanide and those treated with placebo were observed for most other outcome measures. …
Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studies.
Fuentes J, Parellada M, Georgoula C, Oliveira G, Marret S, Crutel V, Albarran C, Lambert E, Pénélaud PF, Ravel D, Ben Ari Y. Fuentes J, et al. Autism Res. 2023 Oct;16(10):2021-2034. doi: 10.1002/aur.3005. Epub 2023 Oct 4. Autism Res. 2023. PMID: 37794745 Clinical Trial.
In both studies, patients were randomized to receive bumetanide oral solution twice daily (BID) or placebo BID during a 6-month double-blind treatment period. ...In both studies, treatment-emergent adverse events that occurred more frequently with bumetanide than pl …
In both studies, patients were randomized to receive bumetanide oral solution twice daily (BID) or placebo BID during a 6-month doubl …
Bumetanide and furosemide.
Brater DC, Chennavasin P, Day B, Burdette A, Anderson S. Brater DC, et al. Clin Pharmacol Ther. 1983 Aug;34(2):207-13. doi: 10.1038/clpt.1983.154. Clin Pharmacol Ther. 1983. PMID: 6872415
We assessed the response to and handling of furosemide and bumetanide in 30 experiments with the former and 46 with the latter in normal subjects. Oral doses of furosemide (20, 40, and 80 mg) were used, and subjects received oral doses of 0.5, 1, and 2 mg bumetanide
We assessed the response to and handling of furosemide and bumetanide in 30 experiments with the former and 46 with the latter in nor …
Bumetanide-induced pseudoporphyria.
Leitao EA, Person JR. Leitao EA, et al. J Am Acad Dermatol. 1990 Jul;23(1):129-30. doi: 10.1016/s0190-9622(08)81209-1. J Am Acad Dermatol. 1990. PMID: 2365864 No abstract available.
Clarifications regarding bumetanide for neonatal seizures.
Staley KJ. Staley KJ. Epilepsia. 2022 Jul;63(7):1863-1867. doi: 10.1111/epi.17278. Epub 2022 May 26. Epilepsia. 2022. PMID: 35524444 Free PMC article. Clinical Trial.
A recent Phase II randomized, controlled trial of bumetanide as an adjunctive treatment for neonatal seizures showed a robust efficacy signal and no evidence of toxicity. Concerns regarding bumetanide as an adjunctive anticonvulsant are addressed here. An adequately …
A recent Phase II randomized, controlled trial of bumetanide as an adjunctive treatment for neonatal seizures showed a robust efficac …
Loop diuretics.
Greger R, Wangemann P. Greger R, et al. Ren Physiol. 1987;10(3-4):174-83. doi: 10.1159/000173128. Ren Physiol. 1987. PMID: 3330836 Review.
Loop diuretics such as furosemide, piretanide, and bumetanide bind reversibly to the Na+2Cl-K+ carrier. This transporter is responsible for the uptake of Cl- into the thick ascending limb segment. ...
Loop diuretics such as furosemide, piretanide, and bumetanide bind reversibly to the Na+2Cl-K+ carrier. This transporter is responsib …
3,625 results